Neoadjuvant immune checkpoint blockade triggers persistent and systemic T reg activation which blunts therapeutic efficacy against metastatic spread of breast tumors

The clinical successes of immune checkpoint blockade (ICB) in advanced cancer patients have recently spurred the clinical implementation of ICB in the neoadjuvant and perioperative setting. However, how neoadjuvant ICB therapy affects the systemic immune landscape and metastatic spread remains to be...

Full description

Saved in:

Bibliographic Details
Published in:	Oncoimmunology Vol. 12; no. 1; p. 2201147
Main Authors:	Blomberg, Olga S., Kos, Kevin, Spagnuolo, Lorenzo, Isaeva, Olga I., Garner, Hannah, Wellenstein, Max D., Bakker, Noor, Duits, Danique E.M., Kersten, Kelly, Klarenbeek, Sjoerd, Hau, Cheei-Sing, Kaldenbach, Daphne, Raeven, Elisabeth A.M., Vrijland, Kim, Kok, Marleen, de Visser, Karin E.
Format:	Journal Article
Language:	English
Published:	United States 31.12.2023
Subjects:	Animals Breast Neoplasms - immunology Breast Neoplasms - therapy CD8-Positive T-Lymphocytes - immunology Humans Immune Checkpoint Inhibitors - therapeutic use Killer Cells, Natural - immunology Lymphocyte Activation Mice Myeloid Cells - immunology Neoadjuvant Therapy Neoplasm Metastasis T-Lymphocytes, Regulatory - immunology regulatory T cells Breast cancer metastasis myeloid cells resistance mechanisms neoadjuvant immune checkpoint blockade
ISSN:	2162-402X, 2162-402X
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!